A phase II trial of postoperative radiotherapy (RT), cisplatin, and panitumumab in patients with high-risk, resected locally advanced squamous cell carcinoma of the head and neck (SCCHN).
Robert L. Ferris(University of Pittsburgh), Athanassios Argiris(The University of Texas at San Antonio Health Science Center), Umamaheswar Duvvuri(City University of New York), Α. Kotsakis(University of Thessaly), G.J. Kubicek, S. Kim, Jonas T. Johnson(University of Pittsburgh), Jennifer R. Grandis(University of California, San Francisco), Dwight E. Heron(Bon Secours Mercy Health)
Cited by 8
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Head and neck squamous cell carcinoma
|Nature Reviews Disease Primers|2020|4k
Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression
|Oral Oncology|2018|802
Immune Landscape of Viral- and Carcinogen-Driven Head and Neck Cancer
|Immunity|2020|688